Gu, Guowei
Tian, Lin http://orcid.org/0000-0003-3661-4453
Herzog, Sarah K.
Rechoum, Yassine
Gelsomino, Luca
Gao, Meng
Du, Lili
Kim, Jin-Ah
Dustin, Derek
Lo, Hin Ching
Beyer, Amanda R.
Edwards, David G.
Gonzalez, Thomas
Tsimelzon, Anna
Huang, Helen J.
Fernandez, Natalie M.
Grimm, Sandra L.
Hilsenbeck, Susan G.
Liu, Dan
Xu, Jun
Alaniz, Alyssa
Li, Shunqiang
Mills, Gordon B. http://orcid.org/0000-0002-0144-9614
Janku, Filip http://orcid.org/0000-0002-8123-4065
Kittler, Ralf
Zhang, Xiang H. -F. http://orcid.org/0000-0002-5674-8670
Coarfa, Cristian http://orcid.org/0000-0002-4183-4939
Foulds, Charles E. http://orcid.org/0000-0003-4908-1473
Symmans, W. Fraser http://orcid.org/0000-0002-1526-184X
Andò, Sebastiano http://orcid.org/0000-0002-5412-7045
Fuqua, Suzanne A. W. http://orcid.org/0000-0001-8886-5161
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (T32 2389301302, T32-CA203690-02, U01 CA217842, CA125123)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Susan G. Komen (SAC110052)
Breast Cancer Research Foundation (BCRF‐19-110)
Cancer Prevention and Research Institute of Texas (RP170005)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (P30 ES030285/P42 ES027725)
Adrienne Helis Malvin Medical Research Foundation (M-2017)
Article History
Received: 24 April 2020
Revised: 31 October 2020
Accepted: 11 November 2020
First Online: 15 December 2020
Change Date: 15 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41388-021-02104-w
Compliance with ethical standards
:
: (1) CEF discloses: an equity position in Coactigon, Inc. (2) FJ discloses: (a) Grant/Research Funding (Institutional): Novartis, Genentech, BioMed Valley Discoveries, Plexxikon, Deciphera, Piqur, Symphogen, Bayer, FujiFilm Corporation and Upsher-Smith Laboratories, Astex, Asana, Astellas, Agios, Proximagen, Bristol-Myers Squibb; (b) Scientific Advisory Board: Deciphera, IFM Therapeutics, Synlogic, Guardant Health, Ideaya, PureTech Health; (c) Paid Consultant: Trovagene, Immunomet, Jazz Pharmaceuticals, Sotio; (d) Ownership Interests: Trovagene. (3) GBM discloses: (a) SAB/Consultant: AstraZeneca, Chrysallis Biotechnology, GSK, ImmunoMET, Ionis, Lilly, PDX Pharmaceuticals, Signalchem Lifesciences, Symphogen, Tarveda, Turbine, Zentalis Pharmaceuticals; (b) Stock/Options/Financial: Catena Pharmaceuticals, ImmunoMet, SignalChem, Tarveda; (c) Licensed Technology: HRD assay to Myriad Genetics, DSP patents with Nanostring. (4) SL discloses: (a) The Washington Unversity PDX development and trial center is supported by NIH 3U54CA224083-02S3. (b) SL has received license fee from Envigo. He received research funding from Pfizer, Takeda Oncology, and Zenopharm, outside of this project.